COMPANIES AND ACADEMICS IN RESIDENCE
Selected start-up companies, and junior academic research groups whose research interests are aligned with ours, are housed in the Centre for Pathway Analysis. Our Milner Therapeutics Consortium pharma partners also have a physical presence, through scientists working on collaborative projects with Cambridge researchers and through hot-desking.
Below you will find details of companies and academics who currently reside within the Milner Therapeutics Institute.
Rockend, co-founded by Dr James Patterson, is developing a next generation cell-based therapeutic. Their platform is based upon genetically engineered iPSCs, and makes use of multiple new advances across the synthetic biology and genome editing space.
Rockend Ltd aim to develop a non-immunogenic, intelligent and safe drug that could be used for the treatment of cancers, autoimmune diseases and various other unmet medical needs.
The Tzelepis group (Milner Therapeutics Institute and Wellcome Sanger Institute) is uncovering epigenetic mechanisms that are implicated in devastating malignancies including acute myeloid leukaemia (AML). His work previously identified several novel RNA-binding/modifying proteins that are essential for AML cell survival, including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, the group is investigating the role of RNA modifications and splicing in cancer initiation and maintenance. As part of the Centre for Pathway Analysis, Kostas will bring vital know-how in both the design of CRISPR screening for improved disease understanding, and also the development of sophisticated in vivo and in vitro assays for genetic and pharmacological validation of promising targets.
The Pathania group (Milner Therapeutics Institute, Dept Oncology and CRUK Cambridge Centre) have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic and epigenetic weaknesses in these tumour models, they hope in the longer term to pave the way to more targeted, precise treatments that can be tailored to each patient. A key area of interest includes how dynamic chromatin remodelling is regulated in neural stem cells and how it becomes co-opted in brain cancer, including paediatric high-grade glioma.